Bayer logo
US MEDICAL AFFAIRS

Publications

Publications

Home/Publications

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated August 28, 2026.

Types of Enhancements Available

Audio Icon
Audio
Infographic Icon
Infographic
Plain language summary icon
Plain Language Summary
Video icon
Video
Digital enhancements icon
Other

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 343    

Filtered results: 343

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: analyses of the phase III ARASENS trial

Fizazi K et al. European Journal of Cancer, 2026; 244: 116888.

Fizazi K, Smith MR, Hussain M, Saad F, Sternberg CN, Crawford ED,
READ
EMAIL

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial

Saad F et al. Eur Urol. 2026 Aug 12; S0302-2838(26)02313-4.

Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M,
READ
EMAIL

Real-world regorafenib use among patients with advanced gastrointestinal stromal tumor in the United States

Denu et al. PLoS One. 2026 Jul 31;21(7):e0353357.

Denu RA, Appukkuttan S, Hocum B, Liao N, Katta A, Heo J,
READ
EMAIL

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial

Trinh Q.-D. et al. Prostate Cancer and Prostatic Diseases. 2026: 1-4.

Trinh QD, George DJ, Shore N, Vjaters E, Olmos D, de Santana Gom,
READ
EMAIL

Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis

Shore N., et al. European Journal of Cancer. 2025;223:115513.

Shore N.; Morgans A.K.; Boegemann M.; Gallagher E.; Paracha N.; ,
READ
EMAIL

Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study

Weinrib R., et al. Oncology and Therapy. 2025.

Weinrib R.; Fortuny J.; Martinez D.; Kollhorst B.; Haug U.; ,
READ
EMAIL

COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials

Rethouse F., et al. ESMO Open. 2025;10(6):105117.

Rethouze F.; Risbourg S.; Schiffler C.; Chabaud S.; de Courrèges,
READ
EMAIL

Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification

Vázquez-Estévez S., et al. Clinical Genitourinary Cancer. 2025;23(3):102338

Vázquez-Estévez S.; Gallardo E.; Fernández-Calvo O.; Juan-Fita M,
READ
EMAIL

Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial: Clinical Studies

Yip D., et al. British Journal of Cancer. 2025;132(10):897-904.

Yip D.; Zalcberg J.; Blay J.-Y.; Eriksson M.; Espinoza D.; Price,
READ
EMAIL

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice

van Riel J.H.H.M.; Donswijk M.L.; Brouwer C.; Gerritsen W.R.; Ta,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2026 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer.

Site last updated 02/2026

Follow Us

Twitter (X) icon Twitter (X) icon
YouTube icon YouTube icon
LinkedIn icon LinkedIn icon
US Medical Affairs QR Code